[May 12, 2014] |
|
Research and Markets: Metastatic Prostate Cancer - Pipeline Review, H1 2014: 9 Companies and 16 Drugs Profiled
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/gq36d8/metastatic)
has announced the addition of the "Metastatic
Prostate Cancer - Pipeline Review, H1 2014" report to their
offering.
This report provides comprehensive information on the therapeutic
development for Metastatic Prostate Cancer, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Metastatic Prostate Cancer and special features on late-stage and
discontinued projects.
The report enhances decision making capabilities and help to create
effective counter strategies to gain competitive advantage. It
strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Reasons to bu
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Metastatic Prostate Cancer
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Metastatic Prostate Cancer pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
AbbVie Inc.
-
Actinium Pharmaceuticals, Inc.
-
Agonox
-
Camurus AB
-
Colby Pharmaceutical Company
-
Fountain Biopharma Inc.
-
MEI Pharma, Inc.
-
OXiGENE, Inc.
-
Progenics Pharmaceuticals, Inc.
Drug Profiles:
-
cabazitaxel
-
pracinostat
-
leuprolide acetate
-
LU-901
-
veliparib
-
Engineered Autologous T Cells + [cyclophosphamide]
-
MEDI-6469
-
CPC (News - Alert)-410
-
Actimab-P
-
Peptide to Inhibit MT1 MMP for Autoimmune Disorders, Inflammation and
Oncology
-
MIP-1095
-
FB-704A
-
Ceramide Analogs
-
KGP-94
-
Vaccine For Oncolytic Newcastle Disease Virus
-
Glutathione Disulfide Liposomal
For more information visit http://www.researchandmarkets.com/research/gq36d8/metastatic
[ Back To TMCnet.com's Homepage ]
|